Description

The integrin αvβ6 is an exciting emerging target for both imaging and therapy across many common tumour types including pancreatic, breast, oesophagus, head and neck, skin, lung and ovarian. Each year an estimated 279,000 αvβ6-positive tumours are diagnosed in the US & UK alone. In addition, αvβ6 is recognised as an exciting target in fibriotic diseases.

Peptides with remarkable affinity and selectivity for αvβ6 have been identified and characterised. In vitro and in vivo data demonstrates the potential of these peptides as the basis for novel PET and SPECT imaging probes, tumour targeting agents and functional inhibitors of αvβ6. Patent family WO2007/039728 protecting the peptide consensus sequence is available for exclusive licensing or collaborative development.

Download the PDF of avß6-binding Peptides for Tumour Targeting

For more information please contact

Dr Hanane Gouizi

+44 (0) 20 3469 6300 .(JavaScript must be enabled to view this email address)